| abstract |
(57) [Problem] To provide an excellent cGMP-specific phosphodiesterase inhibitor. SOLUTION: The formula: [A ring is a benzene ring, W is a nitrogen atom which may have a substituent, Q is C or N, X is a C 1-2 alkylene group which may have an oxo or the like, Z is H 2 or O and Ar each represent an aromatic hydrocarbon group or an aromatic heterocyclic group], or a cGMP-specific phosphodiesterase inhibitor. [Effect] Cardiovascular disease (angina, hypertension, congestive heart failure, pulmonary hypertension, atherosclerosis, patency hypotension, vascular stenosis, peripheral vascular disease, stroke, etc.), obstructive lung Diseases (such as chronic asthma and bronchitis), allergic diseases (such as allergic asthma, allergic rhinitis, and urticaria), diseases characterized by gastrointestinal motility (such as irritable bowel syndrome), glomerular diseases, and urine As a prophylactic / therapeutic agent for tubulointerstitial disease, renal failure, diabetic complications, glaucoma, erectile dysfunction in male mammals including humans, female dysfunction in female mammals including humans, premature birth or dysmenorrhea Can be used. |